Goldman Sachs' top lawyer Kathryn Ruemmler accepted gifts from late sex offender Jeffrey Epstein and advised him on how to address press inquiries regarding his crimes, according to a Reuters review o... ...

Group 1 - Energy Transfer LP (NYSE:ET) is considered one of the best cheap stocks to buy for 2026, with Goldman Sachs raising its price target to $19.00 from $18.50 while maintaining a Neutral rating [1] - The price target adjustment is primarily due to the upcoming USAC/J-W Power acquisition in Q1 2026 and minor changes in assumptions regarding re-contracting in natural gas liquids (NGLs) and crude oil segments, resulting in a roughly 1% increase in long-term estimates [1] - For Q4 2025, Goldman Sachs lowered its EBITDA forecast to $4.16 billion, a 1% decrease from its previous estimate, which is also 2% below the consensus of $4.23 billion [4] Group 2 - For the full year 2025, Goldman Sachs projected EBITDA of $15.96 billion, which aligns with the company's indication that results would fall short of the guided range of $16.1 billion to $16.5 billion [4] - The estimated EBITDA for 2026 is $17.58 billion, or an adjusted $17.37 billion when excluding J-W Power and Hugh Brinson items, closely matching Energy Transfer's guidance of $17.3 billion to $17.7 billion [4] - The bank expects contributions from the PKI acquisition by Susser Holdings Corporation, Waha spread capture, and underlying gas volume growth, although these may be partially offset by lower Midstream margins in Q4 [5] Group 3 - Energy Transfer LP is a midstream energy company that operates one of the largest portfolios of natural gas, crude oil, and NGL pipelines in the United States, including interstate and intrastate pipelines, storage facilities, fractionation plants, and crude oil terminals [6]

Core Viewpoint - Healthpeak Properties, Inc. is a healthcare-focused real estate investment trust (REIT) that has experienced mixed performance in the market, with a significant decline over the past year but a positive year-to-date performance. Performance Summary - Over the past 52 weeks, Healthpeak's shares have declined by 18.1%, while the S&P 500 Index has gained 15.5% [2] - Year-to-date, Healthpeak's stock is up 5.2%, outperforming the S&P 500's increase of 1.9% [2] - Compared to the State Street Real Estate Select Sector SPDR Fund, Healthpeak has also underperformed over the past year but has exceeded its performance year-to-date [3] Recent Developments - On January 7, Healthpeak announced plans for an IPO of Janus Living, a dedicated REIT for senior housing, contributing a portfolio of 34 communities and 10,422 units while retaining a majority stake [4] - The IPO is targeted for the first half of 2026, pending market and regulatory conditions [4] Financial Outlook - For FY2025, analysts project Healthpeak's funds from operations (FFO) to grow by 1.1% year-over-year to $1.83 per share [5] - The company has a strong earnings surprise history, meeting or exceeding consensus estimates in the last four quarters [5] Analyst Ratings - Among 20 analysts covering Healthpeak, the consensus rating is a "Moderate Buy," with eight "Strong Buy," two "Moderate Buy," and ten "Hold" ratings [5] - Goldman Sachs initiated coverage with a "Neutral" rating and a price target of $17, noting the company's portfolio transformation since 2019 [6] - The mean price target of $19.83 indicates a 17.2% premium from current levels, while the highest target of $29 suggests a potential upside of 71.4% [7]

Market Overview - Gold futures experienced a significant decline, dropping below $4,800 per troy ounce, marking the steepest one-day drop since the early 1980s [1] - Silver futures fell more than 13% on the same day, with iShares Silver Trust (SLV) plunging 24.1% last week and SPDR Gold Trust (GLD) retreating 4.7% [1] Federal Reserve Influence - The market sell-off was influenced by President Trump's nomination of Kevin Warsh as the next Chair of the Federal Reserve, interpreted as reducing concerns over the Fed's independence due to Warsh's hawkish policy stance [2] - Evercore ISI noted that markets were "trading Warsh hawkish," suggesting that his appointment could stabilize the dollar, although risks remain [7] Price Corrections and Projections - Analysts from JPMorgan indicated that a correction in silver prices was inevitable after a strong rally, as prices had exceeded projected averages [3] - Despite the recent decline, Goldman Sachs raised its year-end gold price target to $5,400, citing potential upside from increased private-sector investment [4] Dollar Dynamics - A weakening U.S. dollar has been beneficial for gold and commodity investments, recently hitting a four-year low due to yen strength [5] - The decline in the dollar is seen as positive for gold prices, especially in light of U.S. policy uncertainty and trends toward de-dollarization [6] Central Bank Activity - Central bank buying, which has supported gold prices, has slowed in recent months, reducing a key source of upward momentum [10] - The outlook for gold in 2026 appears limited, with reduced geopolitical tensions and a potential fading of dollar weakness [9] Long-term Outlook - The strategic case for de-dollarization remains strong, influenced by Trump's trade policies, which may deter countries from holding U.S. assets [12] - Gold's upside in 2026 is expected to be limited, with silver also facing challenges despite its industrial demand linked to AI [11]

SAN FRANCISCO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Fieldguide, a leading agentic AI-native platform for audit and advisory, today announced a $75 million Series C led by Growth Equity at Goldman Sachs Alternatives, with participation from new investor, Geodesic, and existing investors Bessemer Venture Partners, 8VC, and Thomson Reuters. The financing brings Fieldguide’s total funding to $125 million and values the company at $700 million. Audit and advisory firms are facing a structural capacity problem. Regu ...

Market Overview - The S&P 500 index briefly crossed 7000 points for the first time on January 28, 2026, rebounding nearly 40% since April 2025 lows, with five record closes noted by January 27, 2026 [1] - The Nasdaq Composite has seen modest gains in 2026, while the Russell 2000 has surged nearly 7% year-to-date as of January 29, 2026, outperforming large-cap peers for 14 consecutive trading sessions, the longest streak since 1996 [2] Valuation Concerns - The Shiller S&P 500 price-to-earnings ratio is currently at 41, the highest since the dot-com bubble, while the trailing P/E ratio is at 31.52, significantly above the historical average of 16.2 [3] - Bank of America's head of US equity strategy, Savita Subramanian, indicates that the S&P 500 is expensive, predicting it will reach 7,100 by year-end 2026, which is among the lowest forecasts on Wall Street [3] Investment Strategy - Goldman Sachs analysts predict that value stocks will remain favored if US economic momentum strengthens, noting that these stocks, with forward P/E ratios below 15, have outperformed higher-valuation stocks at the start of the year, achieving a 15% return in the last six months of 2025 [4] Stock Selection Methodology - The list of best cheap stocks for 2026 was created using screeners like TradingView and Finviz, focusing on US-listed stocks with forward P/E ratios between 3 and 15 and a positive upside potential of at least 20%, ranked by hedge fund holdings as of Q3 2025 [7][8] HNI Corporation - HNI Corporation (NYSE:HNI) is highlighted as a top cheap stock for 2026, with a forward P/E of 11.92 and an upside potential of 58.46% [9] - Benchmark Co. raised its price target for HNI to $75 per share from $60, citing a planned acquisition of Steelcase Inc. valued at approximately $2.2 billion, expected to yield annual cost synergies of about $120 million [10] - HNI's shares are priced below historical values, with a P/E ratio of 13.35, and the company has a history of consistent dividend payments over 55 years [11] Sanofi SA - Sanofi SA (NASDAQ:SNY) is also listed as a cheap stock for 2026, with a forward P/E of 9.02 and an upside potential of 25.11% [15] - Citi Research initiated coverage on Sanofi with a Neutral rating and an €85 price target, expressing concerns over pipeline setbacks affecting long-term growth [16] - Sanofi's current valuation reflects these setbacks, with analysts noting that the market is unlikely to reward the stock with a higher multiple without evidence of pipeline improvement [17] - Positive results were reported for Sanofi's experimental medicine amlitelimab in Phase 3 clinical studies for atopic dermatitis, indicating potential for future growth [18]

2) When I saw this, I wondered why I’d never heard this before. Her CIA Agency Award in 2015 was not and still has never been reported by any press outlet whatsoever, not even a fringe one. It’s not in her Wikipedia. It’s not in her extensive current Goldman Sachs bio. ...

Core Insights - Goldman Sachs has initiated coverage of Penguin Solutions with a Buy rating and a revised price target of $25, down from $26, while noting the company's FY2026 outlook is uncertain but remains optimistic about its AI infrastructure momentum [1][4] Financial Performance - In FQ1 2026, Penguin Solutions reported revenue of $343 million, reflecting a 1% year-over-year increase, driven by a 41% annual surge in Integrated Memory business revenue to $137 million due to DDR5 technology and AI computing demand [2] - Advanced Computing revenue increased by 9% sequentially to $151 million [2] Challenges and Future Outlook - The company experienced an 18% sequential decline in its Optimized LED business due to weak demand in China and large US OEM sectors [3] - Management indicated challenges with the high-margin Penguin Edge business, which is expected to wind down by the end of fiscal 2026, alongside a 9% decline in services net sales [3] - Penguin Solutions anticipates a stronger second half of the year by focusing on enterprise and sovereign AI opportunities, leveraging partnerships with Dell, CDW, and Nvidia to diversify its customer base beyond traditional hyperscalers [3]

Core Insights - BioNTech SE (NASDAQ:BNTX) is recognized as a leading high-growth European stock, with Goldman Sachs upgrading its rating from Neutral to Buy and increasing the price target from $115 to $142, emphasizing its pivotal role in oncology [1] - The company has an extensive portfolio targeting a market estimated to exceed $100 billion, with significant results expected in 2026, positioning BioNTech as a potential leader in the next phase of oncology treatments [2] - Despite acknowledging competition in clinical development, Goldman Sachs views BioNTech as having a "unique risk/reward opportunity" in the evolving oncology landscape [3] Company Overview - BioNTech SE is a German biotechnology firm focused on developing and commercializing innovative immunotherapies and vaccines for cancer and infectious diseases [3]

Core Viewpoint - MasterCard demonstrates strong financial performance and growth potential, supported by positive market sentiment and strategic focus on value-added services [2][3][4] Financial Performance - In Q4 2025, MasterCard reported adjusted earnings per share of $4.76, surpassing market expectations of $4.22 to $4.25 [2] - The company achieved an 18% year-over-year increase in net revenue, totaling $8.8 billion [3] - Gross dollar volume rose by 7% to $2.8 trillion, while cross-border volume increased by 14%, indicating robust consumer spending and travel demand [3] Strategic Focus - MasterCard's emphasis on value-added services, including cybersecurity, contributed to a 26% revenue increase in the quarter, marking the fourth consecutive quarter of growth acceleration [4] - These services now account for approximately 44% of total net revenue, highlighting the company's strategy to diversify revenue streams [4] Market Sentiment - Goldman Sachs reaffirmed a "Buy" rating for MasterCard, raising the price target from $710 to $739, reflecting strong confidence in the company's growth trajectory [3] - The stock price increased by 4.29%, equivalent to a $22.36 rise, with a trading range between $520.11 and $544.20 [5] - MasterCard's market capitalization is estimated at around $491.54 billion, reinforcing its strong position in the financial services industry [5]